Have a feature idea you'd love to see implemented?
Let us know!
NERV Minerva Neurosciences Inc
Price (delayed)
$2.12
Market cap
$14.83M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.45
Enterprise value
-$11.8M
Minerva's portfolio of compounds includes: roluperidone (MIN-101), in clinical development for schizophrenia, and MIN-301, in pre-clinical development for Parkinson's disease.
Highlights
The company's net income has surged by 90% QoQ and by 88% YoY
The EPS has surged by 90% year-on-year and by 90% since the previous quarter
Minerva Neurosciences's equity has surged by 51% QoQ but it has decreased by 8% YoY
The company's quick ratio has shrunk by 58% YoY and by 19% QoQ
Key stats
What are the main financial stats of NERV
Market
Valuations
Earnings
Shares outstanding
6.99M
Market cap
$14.83M
Enterprise value
-$11.8M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Net income
-$3.31M
EBIT
-$3.31M
EBITDA
-$3.28M
Free cash flow
-$20.38M
Per share
Balance sheet
Liquidity
EPS
-$0.45
EPS diluted
-$0.45
Free cash flow per share
-$2.69
Book value per share
-$3.1
Revenue per share
$0
TBVPS
$3.69
Total assets
$42.81M
Total liabilities
$64.48M
Debt
$0
Equity
-$21.67M
Working capital
$23.45M
Debt to equity
0
Current ratio
6.23
Quick ratio
5.94
Net debt/EBITDA
8.11
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-6.7%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
-8.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NERV stock price
How has the Minerva Neurosciences stock price performed over time
Intraday
0%
1 week
-7.42%
1 month
-5.36%
1 year
-69.01%
YTD
-65.53%
QTD
-20.6%
Financial performance
How have Minerva Neurosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$24.5M
Net income
-$3.31M
Gross margin
N/A
Net margin
N/A
The company's net income has surged by 90% QoQ and by 88% YoY
NERV's operating income is down by 17% year-on-year but it is up by 7% since the previous quarter
Growth
What is Minerva Neurosciences's growth rate over time
Valuation
What is Minerva Neurosciences stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has surged by 90% year-on-year and by 90% since the previous quarter
Minerva Neurosciences's equity has surged by 51% QoQ but it has decreased by 8% YoY
Efficiency
How efficient is Minerva Neurosciences business performance
Minerva Neurosciences's return on assets has surged by 89% QoQ and by 86% YoY
Dividends
What is NERV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NERV.
Financial health
How did Minerva Neurosciences financials performed over time
The total assets is 34% less than the total liabilities
The company's quick ratio has shrunk by 58% YoY and by 19% QoQ
Minerva Neurosciences's current ratio has shrunk by 57% YoY and by 17% QoQ
The debt is 100% more than the equity
Minerva Neurosciences's equity has surged by 51% QoQ but it has decreased by 8% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.